Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy
D Sun, H Qian, J Li, P Xing - Journal of Biomedical Science, 2024 - Springer
MDM2 has been established as a biomarker indicating poor prognosis for individuals
undergoing immune checkpoint inhibitor (ICI) treatment for different malignancies by various …
undergoing immune checkpoint inhibitor (ICI) treatment for different malignancies by various …
Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
AC Tan, N Pavlakis - International journal of molecular sciences, 2022 - mdpi.com
The management of advanced lung cancer has been transformed with the identification of
targetable oncogenic driver alterations. This includes anaplastic lymphoma kinase (ALK) …
targetable oncogenic driver alterations. This includes anaplastic lymphoma kinase (ALK) …
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
I Attili, N Karachaliou, L Bonanno… - Therapeutic …, 2018 - journals.sagepub.com
Immune checkpoint blockade has modified the treatment landscape for many types of
tumors, including lung cancer. Still our knowledge on the biology of the interaction between …
tumors, including lung cancer. Still our knowledge on the biology of the interaction between …
Non-canonical thinking for targeting ALK-fusion onco-proteins in lung cancer
W Wu, F Haderk, TG Bivona - Cancers, 2017 - mdpi.com
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung
cancer at 3–7% frequency, thus representing an important subset of genetic lesions that …
cancer at 3–7% frequency, thus representing an important subset of genetic lesions that …
Undifferentiated endometrial carcinoma, an immunohistochemical study including PD-L1 testing of a series of cases from a single cancer center
M Al-Hussaini, I Lataifeh, I Jaradat… - International Journal …, 2018 - journals.lww.com
Undifferentiated endometrial carcinoma (UEC) is a rare and poorly recognized entity,
associated with a poor outcome. The clinical, pathologic, and immunohistochemical features …
associated with a poor outcome. The clinical, pathologic, and immunohistochemical features …
Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma
XY Chen, J Zhang, LD Hou, R Zhang… - International journal …, 2018 - journals.sagepub.com
Targeting of the programmed cell-death 1 ligand 1 (PD-L1) signal pathway is a promising
treatment strategy in several cancers. The purpose of this study was to evaluate the clinical …
treatment strategy in several cancers. The purpose of this study was to evaluate the clinical …
Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review
DJ McMahon, R McLaughlin, J Naidoo - Cancers, 2024 - mdpi.com
Simple Summary Patients with non-small cell lung cancer (NSCLC) have a number of
possible systemic treatment options, including targeted therapy, chemotherapy …
possible systemic treatment options, including targeted therapy, chemotherapy …
Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects
Immunogenic cell death (ICD) is clinically relevant because cytotoxicants that kill malignant
cells via ICD elicit anticancer immune responses that prolong the effects of chemotherapies …
cells via ICD elicit anticancer immune responses that prolong the effects of chemotherapies …
PD-1 axis inhibitors in EGFR-and ALK-driven lung cancer: lost cause?
S Gettinger, K Politi - Clinical Cancer Research, 2016 - AACR
Abstract Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer
immunotherapeutics for advanced smoking-associated non–small cell lung cancer. Their …
immunotherapeutics for advanced smoking-associated non–small cell lung cancer. Their …
[HTML][HTML] Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions
EL Schenk - Translational Lung Cancer Research, 2023 - ncbi.nlm.nih.gov
Methods To identify the relevant literature and clinical trials the databases PubMed. gov and
ClinicalTrials. gov were queried with keywords “ALK” and “lung cancer”. PubMed search …
ClinicalTrials. gov were queried with keywords “ALK” and “lung cancer”. PubMed search …